CN1223114A - Rutin and compound rutin mixture for hemostasis - Google Patents
Rutin and compound rutin mixture for hemostasis Download PDFInfo
- Publication number
- CN1223114A CN1223114A CN 98104935 CN98104935A CN1223114A CN 1223114 A CN1223114 A CN 1223114A CN 98104935 CN98104935 CN 98104935 CN 98104935 A CN98104935 A CN 98104935A CN 1223114 A CN1223114 A CN 1223114A
- Authority
- CN
- China
- Prior art keywords
- rutin
- vitamin
- hemorrhage
- injection
- tablet
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to a compound rutin hemostatic mixture formed from rutin (injection or tablet), vitamin C and adrenosem salicylate, in which the rutin, i, e, vitamin P, possesses the function of repairing capillary endothelium, and has the good hemostatic effect for capillary traumatic hemorrhages, such as nosebleed, hemorrhoidal bleeding, nephritic hematuria and gynecological hemorrhage, etc., and the vitamin C and adrenosem salicylate can strengthen the hemostatic action of the rutin, so that the combination of the above-mentioned three medicines can produce strong and quick hemostatic effect, and has no defect of thrombogenesis.
Description
1, rutin and compound rutin mixture for hemostasis
2, the invention belongs to pharmaceutical sanitary field.The present invention is the method invention, and promptly old medicine is newly used--the new purposes of medicine.
3, about three kinds of medicines of composition rutin, vitamin C, carbazochrome salicylate of the spirit of stopping blooding, can be referring to " pharmacology " textbook, " new pharmacology ", " pharmaceutical preparation note ", " data such as newly organized common drug handbook.
4, purpose of the present invention: hemorrhage and bleeding extensively are present in inside and outside, woman, youngster, each section of face, but present domestic field of medicaments not safely and effectively haemostatic medicament meet clinical needs.Thereby the clinical middle haemostatic medicament of widely applying of China is import " reptilase " injection at present, and every price is 50 yuan, uses 2 at every turn, is exactly 100 yuan.And the rutin injection, maximum two, the ternary of every price, vitamin C and carbazochrome salicylate injection, every yuan only.Three medicines share, and hemostatic healing efficacy beats by miles reptilase, but price is 1/10th of a reptilase.Can be China and save a large amount of foreign exchanges.
5, the hemostasis spirit refers to rutin (Citrin, rutin) injection and tablet No. 1.The hemostasis spirit refers to contain rutin and ascorbic compound rutin tablet and injection No. 2.
The hemostasis spirit refers to rutin, vitamin C No. 3, and three kinds of drug combinations of carbazochrome salicylate are the specially good effect mixture for hemostasis.
Rutin, vitamin C and three kinds of medicines of carbazochrome salicylate, its manufacture method ripe already and be widely used in produce actual.The preparation that present domestic pharmaceutical factory produces has rutin tablet (20mg/ sheet), vitamin c tablet (0.1g/ sheet), vitamin c injection (0.5g/ props up), carbazochrome salicylate tablet (2.5mg/ sheet), carbazochrome salicylate injection (10mg/ props up).Still there is not the rutin injection.
For the rutin injection, its manufacture method is also ripe, just because rutin is seldom used (purposes is limited) present in clinical.Hospital does not know with rutin injection and tablet and stops blooding.Tianjin Lik-Sang pharmaceutical factory, Linfen, Shanxi pharmaceutical factory all be shaped on the rutin tablet, but sales volume are limited at present.The core medicine of this hemostasis miraculous cure thing is a rutin, has the effect of repairing capillary endothelium, thereby has good anastalsis.Share with vitamin C, carbazochrome salicylate, can strengthen the anastalsis of rutin.
6, advantage of the present invention:
At present people also know in clinical carbazochrome salicylate and vitamin c are share in hemorrhage, but haemostatic effect is not obvious.The haemostatic effect of other hemorrhage such as dicynone is also undesirable.Thereby have to expensive import medicine " reptilase ".
And rutin, clinical application is limited at present--only be used for the auxiliary treatment of hypertension.
Rutin is used for hemorrhage,, has also shown good haemostatic effect though the tablet oral absorption is less.
The rutin injection then has magical hemostatic healing efficacy.
For general hemorrhagic illness, can stop blooding with rutin separately.For more serious hemorrhage, rutin, vitamin c, carbazochrome salicylate three medicines are share, have rapid and powerful anastalsis.Fully can substituting import one medicine " reptilase ".
7, realize the best way of invention: on the present domestic medical market competent Vitamin C preparation is arranged.Key is the rutin preparation, existing tablet, and dosage little (20mg/ sheet), and oral absorption is relatively poor.So answer large quantities of manufacturing rutin injection, make it become patent drug.And should solve the absorption problem of rutin tablet.Also should study and make hemostasis spirit No. 2 preparations (compound rutin tablet and injection) and hemostasis spirit No. 3 preparations (tablet and injection), to make things convenient for clinical practice.
8, the indication of hemostasis spirit:
Total is to be applicable to that blood capillary is damaging hemorrhage, also can be used for the general hemorrhage of other.Concrete indication is as follows:
A, indication with sure curative effect (hemostasis) has: the hemorrhage (menorrhagia of (1) hemorrhoid hemorrhage (2) epistaxis (3) department of obstetrics and gynecology, functional bleeding, postpartum hemorrhage, gynecilogical operation is hemorrhage) in intracranial hematoma (preventing that hematoma from enlarging) (7) exodontia back hemostasis (8) tonsil enucleation of hemostasis (6) cerebral trauma of (4) traumatic hemorrhage (5) surgery large operation and hematuria (10) spitting of blood (11) idiopathic pulmonary hemosiderosis (12) pneumorrhagia--the hemostasis of nephritis syndrome (13) subarachnoid hemorrhage (14) ophthalmologic operation hemorrhage (15) epidemic hemorrhagic fever of hemostasis (9) acute glomerulonephritis of postoperative.
B, have certain haemostatic effect, the uncertain indication of haemostatic effect:
(1) hemorrhage (3) upper gastrointestinal hemorrhage of haemophiliachemophiliac hemorrhage (2) aplastic anemia.
These examples have almost been contained the overwhelming majority of hemorrhage and bleeding clinically.Certainly also be clinical middle most important parts.Hope can both be carried out the clinical verification of strict science to each problem when examination as to substances.This is a great problem.
Claims (4)
- I have invented new hemorrhage-rutin and compound preparation thereof.This medicine is the core medicine with the rutin, belongs to old medicine usefulness newly, and good anastalsis is arranged.In clinical, have a wide range of applications.Claim:(1) rutin is a Citrin, comprises hesperidin, eriodictin, rutin, claimed disorderly P and products thereof that supports one's family as hemorrhage (comprising tablet and injection).
- (2) claimed compound rutin preparation promptly contains tablet and the injection of vitamin C and rutin.
- (3) claimed mixture for hemostasis---contain the tablet and the injection of rutin, vitamin C, three kinds of compositions of carbazochrome salicylate.
- (4) claimed is the hemostatic agent that composition and other hemorrhage (as vitamin K, Radix Notoginseng powder etc.) are made with the rutin.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 98104935 CN1223114A (en) | 1998-01-13 | 1998-01-13 | Rutin and compound rutin mixture for hemostasis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 98104935 CN1223114A (en) | 1998-01-13 | 1998-01-13 | Rutin and compound rutin mixture for hemostasis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1223114A true CN1223114A (en) | 1999-07-21 |
Family
ID=5218578
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 98104935 Pending CN1223114A (en) | 1998-01-13 | 1998-01-13 | Rutin and compound rutin mixture for hemostasis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1223114A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103249304A (en) * | 2010-05-28 | 2013-08-14 | 新视代皮肤科技公司 | Compositions and methods for treating bruises |
| CN105477413A (en) * | 2015-12-17 | 2016-04-13 | 王丽艳 | Compound medicine for treating vaginal bleeding caused by medical abortion |
| CN105521437A (en) * | 2016-01-12 | 2016-04-27 | 隋妍蕾 | Spider and emei pueraria flower hemorrhoid-treating gel and preparation method thereof |
-
1998
- 1998-01-13 CN CN 98104935 patent/CN1223114A/en active Pending
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103249304A (en) * | 2010-05-28 | 2013-08-14 | 新视代皮肤科技公司 | Compositions and methods for treating bruises |
| CN103249304B (en) * | 2010-05-28 | 2015-07-22 | 新视代皮肤科技公司 | Compositions and methods for treating bruises |
| CN105477413A (en) * | 2015-12-17 | 2016-04-13 | 王丽艳 | Compound medicine for treating vaginal bleeding caused by medical abortion |
| CN105521437A (en) * | 2016-01-12 | 2016-04-27 | 隋妍蕾 | Spider and emei pueraria flower hemorrhoid-treating gel and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Tan et al. | Prospective, randomized trial comparing diathermy and Harmonic Scalpel® hemorrhoidectomy | |
| US5514370A (en) | High dosage topical forms of collagenase | |
| US5852004A (en) | Drug and pharmaceutical composition for the treatment of lesions of the digestive tract | |
| CN1223114A (en) | Rutin and compound rutin mixture for hemostasis | |
| Zakhari et al. | Tranexamic acid in gynecologic surgery | |
| RU2006144397A (en) | APPLICATION OF FACTOR VIIa OR EQUIVALENTS OF FACTOR VIIa TO PREVENT DEVELOPMENT OF HEMORRHEMIA AND / OR Edema AS A RESULT OF INNERCRAIN BLEEDING | |
| WO2005070433A1 (en) | Use of pentoxifylline for the prevention or treatment of ulcers | |
| Kong et al. | Association between intraoperative application of microfibrillar collagen hemostat and anastomotic leakage after anterior resection for rectal cancer: A retrospective case-control study | |
| Yasar et al. | Haemostatic effect of Ankaferd Blood Stopper® seen during adenoidectomy | |
| Sakai et al. | Bacillus cereus brain abscesses occurring in a severely neutropenic patient: successful treatment with antimicrobial agents, granulocyte colony-stimulating factor and surgical drainage | |
| Terzic et al. | Conservative management of massive hematoperitoneum caused by ovulation in a patient with severe form of von Willebrand disease--a case report | |
| EP2609925A2 (en) | Dermatan sulfate for use in the treatment of pathologies wherein metalloproteinases are involved | |
| ELLIOTT et al. | Comparison of lavage or intravenous antibiotics at cesarean section | |
| Bump et al. | Fibrinolysis: a possible factor in the control of postoperative hemorrhage in the patient with hemophilia | |
| Rudd et al. | Febrile morbidity following cefamandole nafate intrauterine irrigation during cesarean section | |
| JP2022541540A (en) | Methods of Forming and Using Hemostatic Hydrocolloids | |
| JPH0692317B2 (en) | Topical anal drug | |
| CN102125559B (en) | Pharmaceutical composition containing pentoxifylline and carbazochrome sodium sulfonate and application thereof | |
| Liu et al. | Management of pelvic lymphocysts by ultrasound-guided aspiration and minocycline sclerotherapy | |
| CN1265819C (en) | Plaster for treating haemorrhoids | |
| Zhao et al. | Prospective comparison of Sapylin and Avitene for reducing hydrops after axillary lymphadenectomy in breast cancer patients | |
| ES2275889T3 (en) | USE OF ANTIDIABETIC AGENTS TO MANUFACTURE A MEDICINAL PRODUCT THAT HAS A CICATRIZING EFFECT. | |
| Lathrop et al. | Abnormal bleeding in obstetrical and gynecological conditions | |
| Saidjalilova et al. | MORPHOLOGICAL ANALYSIS OF MISSED ABORTION | |
| Singh et al. | Role of intravenous tranexamic acid in preventing blood loss following hysterectomy: A randomised controlled trial |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |